Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer:
Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or ci...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Berlin, Heidelberg
Springer Berlin Heidelberg
2012
|
| Ausgabe: | 1st ed. 2012 |
| Schriftenreihe: | Recent Results in Cancer Research
195 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor. In this book, leading investigators in the field provide up-to-date information on a series of important questions, including: - How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis? - What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits? - How are DTCs and CTCs relevant to clinical research and practice? - What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids? - What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development? This book will be of interest and assistance to all who are engaged in the modern management of breast cancer |
| Beschreibung: | 1 Online-Ressource (XIV, 254 Seiten) |
| ISBN: | 9783642281600 |
| DOI: | 10.1007/978-3-642-28160-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV047942927 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220414s2012 |||| o||u| ||||||eng d | ||
| 020 | |a 9783642281600 |9 978-3-642-28160-0 | ||
| 024 | 7 | |a 10.1007/978-3-642-28160-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-3-642-28160-0 | ||
| 035 | |a (OCoLC)1312691688 | ||
| 035 | |a (DE-599)BVBBV047942927 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer |c edited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel |
| 250 | |a 1st ed. 2012 | ||
| 264 | 1 | |a Berlin, Heidelberg |b Springer Berlin Heidelberg |c 2012 | |
| 300 | |a 1 Online-Ressource (XIV, 254 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Recent Results in Cancer Research |v 195 | |
| 520 | |a Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor. In this book, leading investigators in the field provide up-to-date information on a series of important questions, including: - How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis? - What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits? - How are DTCs and CTCs relevant to clinical research and practice? - What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids? - What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development? This book will be of interest and assistance to all who are engaged in the modern management of breast cancer | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Gynecology | |
| 650 | 4 | |a Surgical Oncology | |
| 650 | 4 | |a Pathology | |
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Gynecology | |
| 650 | 4 | |a Surgical oncology | |
| 650 | 4 | |a Pathology | |
| 650 | 4 | |a Cancer research | |
| 650 | 0 | 7 | |a Brustkrebs |0 (DE-588)4008528-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Tumorzelle |0 (DE-588)4186433-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Minimale Resterkrankung |0 (DE-588)1026956056 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Blutkreislauf |0 (DE-588)4134345-1 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Brustkrebs |0 (DE-588)4008528-4 |D s |
| 689 | 0 | 1 | |a Minimale Resterkrankung |0 (DE-588)1026956056 |D s |
| 689 | 0 | 2 | |a Tumorzelle |0 (DE-588)4186433-5 |D s |
| 689 | 0 | 3 | |a Blutkreislauf |0 (DE-588)4134345-1 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Ignatiadis, Michail |4 edt | |
| 700 | 1 | |a Sotiriou, Christos |4 edt | |
| 700 | 1 | |a Pantel, Klaus |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642445873 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642281617 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783642281594 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-642-28160-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_2012 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-033324382 | ||
| 966 | e | |u https://doi.org/10.1007/978-3-642-28160-0 |l UBR01 |p ZDB-2-SME |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804183589851496448 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author2 | Ignatiadis, Michail Sotiriou, Christos Pantel, Klaus |
| author2_role | edt edt edt |
| author2_variant | m i mi c s cs k p kp |
| author_facet | Ignatiadis, Michail Sotiriou, Christos Pantel, Klaus |
| building | Verbundindex |
| bvnumber | BV047942927 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-3-642-28160-0 (OCoLC)1312691688 (DE-599)BVBBV047942927 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| doi_str_mv | 10.1007/978-3-642-28160-0 |
| edition | 1st ed. 2012 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03767nmm a2200661zcb4500</leader><controlfield tag="001">BV047942927</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220414s2012 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642281600</subfield><subfield code="9">978-3-642-28160-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-642-28160-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-3-642-28160-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312691688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047942927</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer</subfield><subfield code="c">edited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1st ed. 2012</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin, Heidelberg</subfield><subfield code="b">Springer Berlin Heidelberg</subfield><subfield code="c">2012</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XIV, 254 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Recent Results in Cancer Research</subfield><subfield code="v">195</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor. In this book, leading investigators in the field provide up-to-date information on a series of important questions, including: - How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis? - What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits? - How are DTCs and CTCs relevant to clinical research and practice? - What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids? - What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development? This book will be of interest and assistance to all who are engaged in the modern management of breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gynecology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Surgical Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gynecology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Surgical oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pathology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer research</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Brustkrebs</subfield><subfield code="0">(DE-588)4008528-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Tumorzelle</subfield><subfield code="0">(DE-588)4186433-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Minimale Resterkrankung</subfield><subfield code="0">(DE-588)1026956056</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Blutkreislauf</subfield><subfield code="0">(DE-588)4134345-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Brustkrebs</subfield><subfield code="0">(DE-588)4008528-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Minimale Resterkrankung</subfield><subfield code="0">(DE-588)1026956056</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Tumorzelle</subfield><subfield code="0">(DE-588)4186433-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Blutkreislauf</subfield><subfield code="0">(DE-588)4134345-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ignatiadis, Michail</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sotiriou, Christos</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pantel, Klaus</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642445873</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642281617</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783642281594</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-642-28160-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_2012</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033324382</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-642-28160-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV047942927 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:40Z |
| indexdate | 2024-07-10T09:25:51Z |
| institution | BVB |
| isbn | 9783642281600 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033324382 |
| oclc_num | 1312691688 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XIV, 254 Seiten) |
| psigel | ZDB-2-SME ZDB-2-SME_2012 |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | Springer Berlin Heidelberg |
| record_format | marc |
| series2 | Recent Results in Cancer Research |
| spelling | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer edited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel 1st ed. 2012 Berlin, Heidelberg Springer Berlin Heidelberg 2012 1 Online-Ressource (XIV, 254 Seiten) txt rdacontent c rdamedia cr rdacarrier Recent Results in Cancer Research 195 Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor. In this book, leading investigators in the field provide up-to-date information on a series of important questions, including: - How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis? - What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits? - How are DTCs and CTCs relevant to clinical research and practice? - What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids? - What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development? This book will be of interest and assistance to all who are engaged in the modern management of breast cancer Oncology Gynecology Surgical Oncology Pathology Cancer Research Oncology Gynecology Surgical oncology Cancer research Brustkrebs (DE-588)4008528-4 gnd rswk-swf Tumorzelle (DE-588)4186433-5 gnd rswk-swf Minimale Resterkrankung (DE-588)1026956056 gnd rswk-swf Blutkreislauf (DE-588)4134345-1 gnd rswk-swf Brustkrebs (DE-588)4008528-4 s Minimale Resterkrankung (DE-588)1026956056 s Tumorzelle (DE-588)4186433-5 s Blutkreislauf (DE-588)4134345-1 s DE-604 Ignatiadis, Michail edt Sotiriou, Christos edt Pantel, Klaus edt Erscheint auch als Druck-Ausgabe 9783642445873 Erscheint auch als Druck-Ausgabe 9783642281617 Erscheint auch als Druck-Ausgabe 9783642281594 https://doi.org/10.1007/978-3-642-28160-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer Oncology Gynecology Surgical Oncology Pathology Cancer Research Oncology Gynecology Surgical oncology Cancer research Brustkrebs (DE-588)4008528-4 gnd Tumorzelle (DE-588)4186433-5 gnd Minimale Resterkrankung (DE-588)1026956056 gnd Blutkreislauf (DE-588)4134345-1 gnd |
| subject_GND | (DE-588)4008528-4 (DE-588)4186433-5 (DE-588)1026956056 (DE-588)4134345-1 |
| title | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer |
| title_auth | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer |
| title_exact_search | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer |
| title_exact_search_txtP | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer |
| title_full | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer edited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel |
| title_fullStr | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer edited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel |
| title_full_unstemmed | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer edited by Michail Ignatiadis, Christos Sotiriou, Klaus Pantel |
| title_short | Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer |
| title_sort | minimal residual disease and circulating tumor cells in breast cancer |
| topic | Oncology Gynecology Surgical Oncology Pathology Cancer Research Oncology Gynecology Surgical oncology Cancer research Brustkrebs (DE-588)4008528-4 gnd Tumorzelle (DE-588)4186433-5 gnd Minimale Resterkrankung (DE-588)1026956056 gnd Blutkreislauf (DE-588)4134345-1 gnd |
| topic_facet | Oncology Gynecology Surgical Oncology Pathology Cancer Research Oncology Gynecology Surgical oncology Cancer research Brustkrebs Tumorzelle Minimale Resterkrankung Blutkreislauf |
| url | https://doi.org/10.1007/978-3-642-28160-0 |
| work_keys_str_mv | AT ignatiadismichail minimalresidualdiseaseandcirculatingtumorcellsinbreastcancer AT sotiriouchristos minimalresidualdiseaseandcirculatingtumorcellsinbreastcancer AT pantelklaus minimalresidualdiseaseandcirculatingtumorcellsinbreastcancer |